Camilla Caprioglio
A5046504062- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Cancer-related cognitive impairment studies
- Functional Brain Connectivity Studies
- Medical Imaging Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Neurobiology of Language and Bilingualism
- Optical Imaging and Spectroscopy Techniques
- Neural dynamics and brain function
- Diet and metabolism studies
- Neurological Disease Mechanisms and Treatments
- Cancer survivorship and care
Forschungszentrum Jülich
2024
University Hospital Cologne
2024
University of Cologne
2024
University of Brescia
2024
University of Geneva
2020-2023
Amyloidosis Foundation
2023
University Hospital of Geneva
2022-2023
Vita-Salute San Raffaele University
2019
Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one main hallmarks Alzheimer disease. However, this technique is currently not widely reimbursed because lack appropriately designed studies demonstrating its clinical effect.To assess effect PET in memory clinic patients.The AMYPAD-DPMS a prospective randomized trial 8 European clinics. Participants were allocated (using minimization method) to 3 study groups based on performance PET: arm 1, early...
Importance Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) at higher risk developing dementia. Some individuals SCD+ undergo amyloid-positron emission tomography (PET) as part research studies frequently wish to know their amyloid status; however, disclosure a positive amyloid-PET result might have psychological risks. Objective To assess outcomes in explore which variables...
ObjectivesHigher-educated patients with Alzheimer disease (AD) can harbor greater neuropathologic burden than those less education despite similar symptom severity.In this study, we assessed whether observation is also present in potential preclinical AD stages, namely individuals subjective cognitive decline and clinical features increasing likelihood (SCD+). MethodsAmyloid-PET information ([ 18 F]Flutemetamol or [ F]Florbetaben) of SCD+, mild impairment (MCI), were retrieved from the...
Assess the individual and combined diagnostic value of amyloid-PET tau-PET in a memory clinic population.Clinical reports 136 patients were randomly assigned to two pathways: AMY-TAU, is presented before tau-PET; TAU-AMY, amyloid-PET. Two neurologists independently assessed all with balanced randomized design, expressed etiological diagnosis confidence (50-100%) three times: (i) at baseline based on routine workup, (ii) after first exam (amyloid-PET for AMY-TAU pathway, TAU-AMY pathway),...
Recent advances occurred in the field of Alzheimer's disease (AD) biomarkers and introduction a research framework grounded on biomarker-based definition AD might have fostered an increased clinical use biomarkers. For this reason, up-to-date depiction is needed.To investigate main patients with mild cognitive impairment (MCI) by examining beliefs preferences professionals (clinicians biomarker experts) European Disease Consortium (EADC).150 filled online survey from May to September 2020....
AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features discuss representativeness cohort.
Background: The dorsal anterior cingulate cortex (dACC) is a key network hub for cognitive control and environmental adaptation. Previous studies have shown that task-based functional activity in this area constrained by individual differences sulcal pattern, morphologic feature of anatomy determined during fetal life stable throughout development. Methods: By using anatomical magnetic resonance imaging seed-based resting-state connectivity (rsFC), we explored the influence pattern...
Abstract Background AMYPAD‐DPMS is a European, multicenter, prospective, interventional, randomized controlled study. It aims to assess clinical utility and cost‐effectiveness of amyloid‐PET. recruited individuals with Subjective Cognitive Decline plus (SCD+), syndromic diagnosis Mild Impairment (MCI) dementia. Here, we describe the quantitative results basal amyloid PET performed in these participants. Method Until end recruitment on October 30 th , 2020, 844 participants were included from...
Abstract Background Higher educated patients with MCI can tolerate more neuropathology than lower similar clinical impairment. It is not known whether this observation also accounts for potential preclinical stages of AD, namely subjective cognitive decline plus (SCD+). Method Data 197 SCD+ individuals, 227 and 157 AD were included, which collected as part the AMYPAD‐DPMS cohort (https://amypad.eu/). First, median education in years was computed across AD‐spectrum groups each 8 European...
Abstract Background In clinical practice, visual assessment of amyloid‐PET images results in a binary classification (negative or positive) amyloid status. While this approach has shown high utility, the expected approval disease‐modifying treatments warrants need for objective burden quantification, to further support high‐confidence diagnosis Alzheimer’s disease (AD) and treatment decisions. We investigated two widely available quantification methods, i.e. Centiloid (CL) z‐scores optimize...
Abstract Background Amyloid‐PET allows the assessment of amyloid deposition, one main hallmarks Alzheimer’s disease. However, in most countries, this exam is not routinely used clinical practice. Several studies have assessed physician‐centered outcomes, yet often without a randomized study design. In addition, choice to reimburse amyloid‐PET depends also on its cost‐effectiveness and safety procedure disclosure. Method We cost‐effectiveness, result disclosure AMYPAD‐DPMS cohort....
Abstract Background Amyloid‐PET allows the direct assessment of amyloid deposition, one main hallmarks Alzheimer’s disease. However, this technique is currently not or incompletely reimbursed due to lack randomized controlled studies demonstrating a clinical impact. Method AMYPAD‐DPMS prospective, multicenter, study. Patients with subjective cognitive decline plus (SCD+), mild impairment (MCI) dementia from 8 European memory clinics were into three study arms: ARM1, amyloid‐PET performed...
Abstract Background . This study aims to investigate the clinical use of main Alzheimer’s disease (AD) biomarkers in patients with mild cognitive impairment (MCI) by examining beliefs and preferences clinicians biomarker experts European Disease Consortium (EADC). Methods Out 306 contacted EADC professionals, 150 (101 clinicians, 43 experts, 6 falling into other categories) filled an online survey from May September 2020. The investigated were: medial temporal lobe atrophy score (MTA) on...
Abstract Background Alzheimer’s disease (AD) is defined as a clinic‐biological characterized by the abnormal deposition of amyloid and tau in brain. AD biomarkers offer perspective to confirm presence pathology vivo supports their increasing use clinical practice. The aim this study investigate main biomarkers, focusing on amyloid‐PET tau‐PET, examining beliefs preferences clinicians (neurologists, geriatricians, psychiatrists) well biomarker experts (nuclear medicine, radiology, laboratory...